New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
10:00 EDTTSN, PCYC, MWE, FGP, COST, AGNC, ZION, SBH, MSTR, LSTR, FDO, COLM, ALB, WPX, PFS, MTDR, ONE, DCO, BOHOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Albemarle (ALB) upgraded to Buy from Hold at Topeka... American Capital Agency (AGNC) upgraded to Buy from Hold at Wunderlich... Bank of Hawaii (BOH) upgraded to Buy from Neutral at DA Davidson... Columbia Sportswear (COLM) upgraded to Hold from Sell at McAdams Wright... Costco (COST) upgraded to Conviction Buy from Neutral at Goldman... Ducommun (DCO) upgraded to Buy from Neutral at DA Davidson... Family Dollar (FDO) upgraded to Neutral from Underweight at Piper Jaffray... Ferrellgas Partners LP (FGP) upgraded to Neutral from Sell at Citigroup... Higher One (ONE) upgraded to Overweight from Underweight at Piper Jaffray... Landstar System (LSTR) upgraded to Buy from Hold at BB&T... MarkWest Energy (MWE) upgraded to Buy from Hold at Wunderlich... Matador (MTDR) upgraded to Outperform from Market Perform at BMO Capital... MicroStrategy (MSTR) upgraded at JMP Securities... Pharmacyclics (PCYC) upgraded to Outperform from Market Perform at Leerink... Provident Financial (PFS) upgraded at Sterne Agee... Sally Beauty (SBH) upgraded to Buy from Neutral at Citigroup... Tyson Foods (TSN) upgraded to Buy from Hold at Miller Tabak... WPX Energy (WPX) upgraded to Accumulate from Hold at Tudor Pickering... Zions Bancorp (ZION) upgraded at Bernstein.
News For ALB;AGNC;BOH;COLM;COST;DCO;FDO;FGP;ONE;LSTR;MWE;MTDR;MSTR;PCYC;PFS;SBH;TSN;WPX;ZION From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
December 9, 2014
15:18 EDTCOST, FGPNotable companies reporting before tomorrow's open
Subscribe for More Information
12:29 EDTTSNTyson Foods volatility at low end of range into investor meeting
Subscribe for More Information
07:32 EDTZIONZions Bancorp outlook has improved, says SunTrust
Subscribe for More Information
07:29 EDTCOSTCostco December weekly volatility increases into Q1 and outlook
Costco December weekly call option implied volatility is at 32, December is at 16, January is at 15, April is at 14; compared to its 26-week average of 16 according to Track Data suggesting larger near term price movement into the expected release of Q1 results on December 10.
05:50 EDTPCYCPharmacyclics data demonstrates safety, durability response
New, 27-month IMBRUVICA median follow-up data announced by Pharmacyclics (PCYC) support the use of IMBRUVICA over longer periods of time in patients with relapsed/refractory mantle cell lymphoma, or MCL, an aggressive type of lymphoma. More than 30% of IMBRUVICA patients remained progression-free after two years with no new or unexpected adverse events occurring during that time. Nearly half of the 111 patients treated were still living at the time of the data analysis. A second Phase II trial looked at IMBRUVICA's efficacy and safety as a single-agent treatment for MCL patients who previously had received rituximab combination therapy and at least two cycles of bortezomib. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:43 EDTPCYCPharmacyclics reports IMBRUVICA data shows 84% PFS rate at one year
Pharmacyclics (PCYC) announced new, longer term data in IMBRUVICA patients with relapsed/refractory chronic lymphocytic leukemia, or CLL, including high-risk CLL patients with deletion 17p. Results from the Phase III RESONATE trial demonstrated an 84% progression-free survival, or PFS, rate in all patients with previously treated CLL or small lymphocytic lymphoma, or SLL, who received IMBRUVICA and a 94% PFS rate in patients who received only one prior therapy at 12 months. Separately, follow-up data was reported from Phase II RESONATE-17, or PCYC-1117, the largest prospective trial dedicated to studying CLL or SLL patients with del 17p. The data showed that IMBRUVICA was associated with an 83% overall response rate, or ORR, at a median follow up of 11.5 months. At 12 months, the estimated PFS was 79%. These results and additional data were presented here at the 56th American Society of Hematology, or ASH, Annual Meeting, highlighting IMBRUVICA's sustained efficacy in relapsed/refractory patients who have received at least one prior therapy. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:27 EDTPCYCPharmacyclics IMBRUVICA Phase II combination data shows positive profile
Subscribe for More Information
December 8, 2014
17:54 EDTMTDRMatador expects to produce in excess of 1M barrels of oil in Q4
Subscribe for More Information
17:41 EDTMTDRMatador provides operational update
Matador Resources is pleased to provide the following update of its ongoing operations. As previously announced, Matador plans to host a live conference call for its shareholders on Tuesday, December 9, at 9:00 a.m. CST. The purpose of this call is to provide Matador’s shareholders with an update on the company’s fourth quarter performance to date, answer questions from shareholders, and discuss the company’s outlook for the remainder of 2014 and for 2015 with Joe Foran, Chairman and CEO, and other members of Matador’s senior management team in light of the recent decline in West Texas Intermediate oil prices below $70 per barrel. The company is studying its planned 2015 capital investment program in light of this recent decline in oil prices, but does not plan to provide specific 2015 guidance during this conference call. The company intends to provide specific 2015 guidance at its upcoming Analyst Day scheduled for January 15, 2015 in Dallas, Texas.
13:45 EDTPCYCTG Therapeutics says TG-1101 well tolerated in Phase 2 study
Subscribe for More Information
08:32 EDTPCYCTrout Group to hold events at ASH 2014
Subscribe for More Information
December 7, 2014
14:54 EDTPCYCIMBRUVICA data suggests promise in multiple myeloma
Subscribe for More Information
December 5, 2014
13:16 EDTTSNTyson Foods to host investor meeting
Subscribe for More Information
12:03 EDTFDOFive Below plummets after Q4, FY14 outlooks trail analysts' estimates
Subscribe for More Information
10:03 EDTFDOFamily Dollar sees Dollar General needing to divest over 3.4K stores, CNBC says
Subscribe for More Information
10:00 EDTTSNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:19 EDTFDODollar General says remains committed to purchase of Family Dollar
Dollar General Corporation (DG) issued the following statement in response to comments made by Dollar Tree (DLTR) regarding its view of potential store divestitures that may be required by the FTC in either a Dollar Tree/Family Dollar Stores (FDO) or a Dollar General/Family Dollar combination. Dollar General’s documents and data tell a very different story from that contained in the press release issued today by Dollar Tree. As Dollar General previously has stated, Walmart (WMT), not Family Dollar, is the primary driver regarding Dollar General’s strategic pricing decisions, and more than 90% of Dollar General’s SKUs are nationally priced. Dollar General is confident that its approach to strategic and pricing decisions is both correct and superior to that of Family Dollar and Dollar General has no intention of adopting a flawed strategy -- either now or after an acquisition of Family Dollar -- that it believes would impair its ability to compete with Walmart and lead to inferior financial performance. Dollar General is actively engaged in discussions with the FTC regarding the extent of potential divestitures that would be required in connection with an acquisition of Family Dollar and has been making good progress. Over the past few weeks, Dollar General has provided the FTC with tens of thousands of documents supporting the above facts and its broad view of competition. There is no reason to believe that the FTC would take into account only Family Dollar’s documents and data or afford them greater significance than Dollar General's own evidence. As stated in Dollar General's press release of December 4, Dollar General will continue to work with the FTC and expects to provide an update in sufficient time to allow Family Dollar shareholders to review such information prior to the Family Dollar shareholders’ meeting now scheduled for December 23.
07:29 EDTCOSTCostco December weekly volatility elevated into Q1 and outlook
Costco December weekly call option implied volatility is at 22, December is at 16, January is at 15, April is at 14; compared to its 26-week average of 16 according to Track Data suggesting larger near term price movement into the expected release of Q1 results on December 10.
06:40 EDTTSNTyson Foods upgraded to Conviction Buy from Buy at Goldman
Subscribe for More Information
06:09 EDTFDODollar Tree provides update on FTC review of pending acquisition of Family Dolla
Dollar Tree (DLTR) announced that it was providing an update regarding the status of the FTC's review of its pending acquisition of Family Dollar (FDO). Dollar Tree and Family Dollar have been actively engaging with the staff of the FTC as they review the pending merger. The company said, "The staff of the FTC is very focused on the discount retail sector (including how Family Dollar’s current pricing rules would impact store prices in a merger transaction) and has indicated that some divestitures will be required for the Pending Merger, which we believe will be no more than our original commitment in the July 27, 2014, Merger Agreement. Dollar Tree will work diligently with the FTC staff over the next few weeks concerning divestitures. Given the relatively small number of divestitures our transaction implicates, Dollar Tree does not expect any such divestiture to have a material impact on its plans for the combined organization. Furthermore, we believe that we will be in a position to complete the financing for the Pending Merger in January 2015 and to complete the Pending Merger as early as February 2015... In connection with its unsolicited tender offer for Family Dollar, Dollar General (DG) continues to refuse to agree to a “hell-or-high-water” commitment. Based on the foregoing concerns regarding the Pending Merger, Dollar Tree believes that the FTC may require divestitures far in excess of the 1,500 stores that Dollar General has offered to divest in its tender offer for Family Dollar... The special meeting of Family Dollar shareholders to vote on the Pending Merger is currently scheduled for December 23, 2014. To facilitate the FTC’s continued review, and in light of the practicalities associated with the transaction, Dollar Tree and Family Dollar have agreed not to close the Pending Merger until January 30, 2015, unless the FTC completes its review of the Pending Merger and terminates the waiting period at an earlier date. Dollar Tree will continue to provide additional information as the special meeting date approaches."
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use